

•	E G
FORM PTO-1449	The C
(REV. 7-80)	G TOADGAND
(1121.1 00)	MADE

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 478.1072US

SERIAL NO.: 10/552,231

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

 $\label{eq:APPLICANT(S): John STANIFORTH et al.} APPLICANT(S): \ \ John STANIFORTH et al.$ 

FILING DATE: April 14, 2004

GROUP: 1617

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOC	UMEN	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	20	02	00	06	9	3	3	1/17/2002	Gupta et al.	514	295	
	AB	5	6	9	9	7	8	9	12/23/1997	Hendricks, Mark R.	128	203.15	
	AC	<u> </u>						ļ					
_	AD			<u> </u>				ļ					
	AE												
	AF												
	AG												

## FOREIGN PATENT DOCUMENTS

	DOC	UMEN	T NUME	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
АН													
Al													
AJ													
AK													
AL													

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	Shargel, et al.; Comprehensive Pharmacy Review; 3rd Edition, Pharmaceutical Sciences, Part 1, Chapter 1, pp.1-6 (1997).
AN	Lucas, et al.; "Enhancement of Small Particle Size Dry Powder Aerosol Formulations Using An Ultra Low Density Additive," Pharmaceutical Research, Vol. 16, No. 10, pp. 1643-1647 (1999).
AO	Ensuring Patient Care, The Role Of The HFC MDI, 2 <sup>nd</sup> Edition, pp. 15-21, International Pharmaceutical Aerosol Consortium, (June 1999).
AP	
AQ	
AR	
	AN AO AP AQ

**EXAMINER** 

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.